Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment
Elisa Becze BA, ELS, Editor
Voice
Description
A new class of drugs, antibody-drug conjugates (ADCs), combines the specificity of targeted therapy with the cytotoxicity of chemotherapy for a powerhouse effect against certain types of cancer variants. Here’s what you need to know about this novel treatment modality.